Treffer: Bioengineering Living Biohybrid Therapeutics for Synergistic H 2 S Gaseous-Photothermal Cancer Eradication.

Title:
Bioengineering Living Biohybrid Therapeutics for Synergistic H 2 S Gaseous-Photothermal Cancer Eradication.
Authors:
Deng X; Department of Pharmacology, School of Medicine, Shenzhen Campus of Sun Yat-Sen University, Shenzhen, 518107, P. R. China.; Center for Materials Synthetic Biology, State Key Laboratory of Quantitative Engineering Biology, Shenzhen Institute of Synthetic Biology, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, 518000, P. R. China., Zhang Y; Department of Pharmacology, School of Medicine, Shenzhen Campus of Sun Yat-Sen University, Shenzhen, 518107, P. R. China.; Center for Materials Synthetic Biology, State Key Laboratory of Quantitative Engineering Biology, Shenzhen Institute of Synthetic Biology, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, 518000, P. R. China., Wu C; Materdicine Lab, School of Life Sciences, Shanghai University, Shanghai, 200444, P. R. China., Liang Y; Department of Pharmacology, School of Medicine, Shenzhen Campus of Sun Yat-Sen University, Shenzhen, 518107, P. R. China.; Center for Materials Synthetic Biology, State Key Laboratory of Quantitative Engineering Biology, Shenzhen Institute of Synthetic Biology, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, 518000, P. R. China., Ding J; Department of Chemical and Biomolecular Engineering, National University of Singapore, Singapore, 117585, Singapore., Yu C; Department of Pharmacology, School of Medicine, Shenzhen Campus of Sun Yat-Sen University, Shenzhen, 518107, P. R. China., Zhang X; Department of Pharmacology, School of Medicine, Shenzhen Campus of Sun Yat-Sen University, Shenzhen, 518107, P. R. China., Lin Y; Department of Chemical and Biomolecular Engineering, National University of Singapore, Singapore, 117585, Singapore., Liang J; Department of Pharmacology, School of Medicine, Shenzhen Campus of Sun Yat-Sen University, Shenzhen, 518107, P. R. China., Duan F; Department of Pharmacology, School of Medicine, Shenzhen Campus of Sun Yat-Sen University, Shenzhen, 518107, P. R. China., Feng W; Materdicine Lab, School of Life Sciences, Shanghai University, Shanghai, 200444, P. R. China., Chen Y; Materdicine Lab, School of Life Sciences, Shanghai University, Shanghai, 200444, P. R. China., Gao X; Center for Materials Synthetic Biology, State Key Laboratory of Quantitative Engineering Biology, Shenzhen Institute of Synthetic Biology, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, 518000, P. R. China.
Source:
Advanced healthcare materials [Adv Healthc Mater] 2026 Jan; Vol. 15 (1), pp. e01621. Date of Electronic Publication: 2025 Aug 18.
Publication Type:
Journal Article
Language:
English
Journal Info:
Publisher: Wiley-VCH Country of Publication: Germany NLM ID: 101581613 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2192-2659 (Electronic) Linking ISSN: 21922640 NLM ISO Abbreviation: Adv Healthc Mater Subsets: MEDLINE
Imprint Name(s):
Original Publication: Weinheim : Wiley-VCH, 2012-
References:
a) E. Joulia, C. M. Metallo, Nat. Metab. 2023, 5, 1456;.
b) Y. Zhang, J. Fang, S. Ye, Y. Zhao, A. Wang, Q. Mao, C. Cui, Y. Feng, J. Li, S. Li, M. Zhang, H. Shi, Nat. Commun. 2022, 13, 1685;.
c) R. Kumar, V. Vitvitsky, A. Sethaudom, R. Singhal, S. Solanki, S. Alibeckoff, H. L. Hiraki, H. N. Bell, A. Andren, B. M. Baker, C. A. Lyssiotis, Y. M. Shah, R. Banerjee, Nat. Chem. Biol. 2024, 20, 1294.
a) C. H. Switzer, S. Kasamatsu, H. Ihara, P. Eaton, Proc. Natl. Acad. Sci. USA 2023, 120, 2205044120;.
b) Q. Zong, J. Li, Q. Xu, Y. Liu, K. Wang, Y. Yuan, Nat. Commun. 2024, 15, 7558.
a) F. Cai, H. Xu, N. Cao, X. Zhang, J. Liu, Y. Lu, J. Chen, Y. Yang, J. Cheng, Z. C. Hua, H. Zhuang, Cell Death Dis. 2020, 11, 33;.
b) S. Yu, Z. Cao, F. Cai, Y. Yao, X. Chang, X. Wang, H. Zhuang, Z.‐C. Hua, Cell Death Dis. 2024, 15, 463.
S. Lu, Y. Gao, X. Huang, X. Wang, Int. J. Oncol. 2014, 44, 1259.
T. Murata, T. Sato, T. Kamoda, H. Moriyama, Y. Kumazawa, N. Hanada, Exp. Cell Res. 2014, 320, 247.
a) J. Li, L. Xie, B. Li, C. Yin, G. Wang, W. Sang, W. Li, H. Tian, Z. Zhang, X. Zhang, Q. Fan, Y. Dai, Adv. Mater. 2021, 33, 2008481;.
b) L. Wu, Y. Liu, W. Zeng, Y. Ishigaki, S. Zhou, X. Wang, Y. Sun, Y. Zhang, X. Jiang, T. Suzuki, D. Ye, J. Am. Chem. Soc. 2023, 145, 27838.
a) G. Li, H. Lei, Y. Yang, X. Zhong, F. Gong, Y. Gong, Y. Zhou, Y. Zhang, H. Shi, Z. Xiao, Z. Dong, L. Cheng, Adv. Sci. 2022, 9, 2201069;.
b) R. Malla, R. Marni, A. Chakraborty, M. A. Kamal, J. Pharm. Anal. 2022, 12, 221.
a) C. R. Gurbatri, N. Arpaia, T. Danino, Science 2022, 378, 858;.
b) M. R. Charbonneau, V. M. Isabella, N. Li, C. B. Kurtz, Nat. Commun. 2020, 11, 1738;.
c) J. Hahn, S. Ding, J. Im, T. Harimoto, K. W. Leong, T. Danino, Nat. Rev. Bioeng. 2024, 2, 120;.
d) A. Rodrigo‐Navarro, S. Sankaran, M. J. Dalby, A. del Campo, M. Salmeron‐Sanchez, Nat. Rev. Mater. 2021, 6, 1175.
a) S. Pi, W. Yang, W. Feng, R. Yang, W. Chao, W. Cheng, L. Cui, Z. Li, Y. Lin, N. Ren, C. Yang, L. Lu, X. Gao, Nat. Sustain. 2023, 6, 1673;.
b) J. Chen, L. Gan, Y. Han, G. Owens, Z. Chen, J. Hazard. Mater. 2024, 466, 133622.
M. B. Akolpoglu, Y. Alapan, N. O. Dogan, S. F. Baltaci, O. Yasa, G. Aybar Tural, M. Sitti, Sci. Adv. 2022, 8, abo6163.
Y. C. Chen, Y. T. Li, C. L. Lee, Y. T. Kuo, C. L. Ho, W. C. Lin, M. C. Hsu, X. Long, J. S. Chen, W. P. Li, C. H. Su, A. Okamoto, C. S. Yeh, Nat. Nanotechnol. 2023, 18, 1492.
M. Huo, L. Wang, L. Zhang, C. Wei, Y. Chen, J. Shi, Angew. Chem. Int. Ed. Engl. 2020, 59, 1906.
X. C. Deng, J. L. Liang, S. M. Zhang, Y. Z. Wang, Y. T. Lin, R. Meng, J. W. Wang, J. Feng, W. H. Chen, X. Z. Zhang, Adv. Mater. 2024, 36, 2405673.
M. Chen, L. Xia, C. Wu, Z. Wang, L. Ding, Y. Xie, W. Feng, Y. Chen, Chem. Soc. Rev. 2024, 53, 8306.
a) J. Xu, S. Yang, L. Yang, Trends Biotechnol. 2022, 40, 381;.
b) J. Tian, W. Deng, Z. Zhang, J. Xu, G. Yang, G. Zhao, S. Yang, W. Jiang, Y. Gu, Nat. Commun. 2023, 14, 7758;.
c) F. Thoma, B. Blombach, Essays Biochem. 2021, 65, 381.
a) J. A. Hayes, A. W. Lunger, A. S. Sharma, M. T. Fernez, R. L. Carrier, A. N. Koppes, R. Koppes, B. M. Woolston, Cell Rep. 2023, 42, 113481;.
b) D. J. Braccia, X. Jiang, M. Pop, A. B. Hall, Front. Microbiol. 2021, 12, 705583.
a) S. W. Bang, D. S. Clark, J. D. Keasling, Appl. Environ. Microbiol. 2000, 66, 3939;.
b) Q. Qi, H. Zhang, Z. Jin, C. Wang, M. Xia, B. Chen, B. Lv, L. P. Diaz, X. Li, R. Feng, M. Qiu, Y. Li, D. Meseguer, X. Zheng, W. Wang, W. Song, H. Huang, H. Wu, L. Chen, M. Schneeberger, X. Yu, Nat. Metab. 2024, 6, 1601.
a) A. Curcio, A. V. de Walle, E. Benassai, A. Serrano, N. Luciani, N. Menguy, B. B. Manshian, A. Sargsian, S. Soenen, A. Espinosa, A. Abou‐Hassan, C. Wilhelm, ACS Nano 2021, 15, 9782;.
b) H. Xiang, L. Zhao, L. Yu, H. Chen, C. Wei, Y. Chen, Y. Zhao, Nat. Commun. 2021, 12, 218.
N. Li, Q. Sun, Z. Yu, X. Gao, W. Pan, X. Wan, B. Tang, ACS Nano 2018, 12, 5197.
a) M. Y. Zhang, G. J. Dugbartey, S. Juriasingani, A. Sener, Int. J. Mol. Sci. 2021, 22, 6452;.
b) G. K. Kolluru, R. E. Shackelford, X. Shen, P. Dominic, C. G. Kevil, Nat. Rev. Cardiol. 2023, 20, 109.
J. Cheng, Y. Zhu, Y. Dai, L. Li, M. Zhang, D. Jin, M. Liu, J. Yu, W. Yu, D. Su, J. Zou, X. Chen, Y. Liu, Angew. Chem. Int. Ed. Engl. 2023, 62, 202304312.
a) A. R. Chowdhury, J. Zielonka, B. Kalyanaraman, R. C. Hartley, M. P. Murphy, N. G. Avadhani, Redox Biol. 2020, 36, 101606;.
b) B. Qiu, F. Zandkarimi, C. T. Bezjian, E. Reznik, R. K. Soni, W. Gu, X. Jiang, B. R. Stockwell, Cell 2024, 187, 1177.
S. Kishi, H. Nagasu, K. Kidokoro, N. Kashihara, Nat. Rev. Nephrol. 2024, 20, 101.
a) X. N. Wu, J. Y. Li, Q. He, B. Q. Li, Y. H. He, X. Pan, M. Y. Wang, R. Sang, J. C. Ding, X. Gao, Z. Wu, W. Liu, Proc. Natl. Acad. Sci. USA 2024, 121, 2219352120;.
b) S. C. S. Lee, A. H. A. Pyo, M. Koritzinsky, Sci. Adv. 2023, 9, adj6409.
C. Glorieux, S. Liu, D. Trachootham, P. Huang, Nat. Rev. Drug Discov. 2024, 23, 583.
H. S. Jung, J. H. Lee, K. Kim, S. Koo, P. Verwilst, J. L. Sessler, C. Kang, J. S. Kim, J. Am. Chem. Soc. 2017, 139, 9972.
Grant Information:
52272279 National Natural Science Foundation of China; 52072393 National Natural Science Foundation of China; 32000543 National Natural Science Foundation of China; 82272104 National Natural Science Foundation of China; ZDSYS20220606100606013 Shenzhen Science and Technology Program; ZDSYS20220606100803007 Shenzhen Science and Technology Program; RCYX20221008092901004 Shenzhen Science and Technology Program; 23S11900900 Shanghai Science and Technology Committee Biomedical Program; 2024B1515020102 Guangdong Basic and Applied Basic Research Foundation; 2024A1515010500 Guangdong Basic and Applied Basic Research Foundation; 2021YFA0909900 Key Technologies Research and Development Program
Contributed Indexing:
Keywords: hydrogen sulfide; living biohybrid therapeutics; living biomaterials; synergy therapy; synthetic biology
Substance Nomenclature:
YY9FVM7NSN (Hydrogen Sulfide)
789U1901C5 (Copper)
0 (Reactive Oxygen Species)
Entry Date(s):
Date Created: 20250818 Date Completed: 20260110 Latest Revision: 20260110
Update Code:
20260111
DOI:
10.1002/adhm.202501621
PMID:
40820708
Database:
MEDLINE

Weitere Informationen

Hydrogen sulfide (H <subscript>2</subscript> S)-mediated gaseous therapies feature high therapeutic efficacy and biosafety in cancer treatment, but conventional H <subscript>2</subscript> S delivery protocols suffer from poor tumor specificity and uncontrollable release. Here, a living therapeutic biohybrid is developed that integrates engineered microbes for in situ H <subscript>2</subscript> S production with self-mineralized copper sulfide (CuS) nanoparticles, enabling synergistic H <subscript>2</subscript> S gaseous-photothermal cancer treatment. These engineered facultative anaerobic bacteria Vibrio natriegens continuously produce H <subscript>2</subscript> S and synthesize CuS nanoparticles, forming Bac@CuS living biohybrids that inhibit the mitochondrial electron transport chain through H <subscript>2</subscript> S production, leading to increased reactive oxygen species production and subsequent apoptosis of cancer cells. Concurrently, Bac@CuS-mediated photothermal effect induces hyperthermia, further impairing mitochondrial function and enhancing cancer-cell death. In vivo studies demonstrate that Bac@CuS living biohybrids feature excellent biocompatibility and have achieved a 95.4% tumor inhibition rate in the breast tumor-bearing mouse model. The biohybrid therapeutic platform enables the engineered bacteria to produce non-native effectors alongside with nanoparticles, integrating synthetic biology with nanotechnology and offering a novel approach for efficient cancer eradication.
(© 2025 Wiley‐VCH GmbH.)